The Safety, Tolerability and Pharmacokinetic Study of RAY1225

NCT05835752 | Completed Phase 1

• 1 other identifier: RAY1225-22-01
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225

Conditions

Obese; Healthy

Keywords

obesity; GLP-1; GIP

Outcome Measures

Primary Outcomes (2)

• Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)

  A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported

  Baseline through Day 29 (Part A)

• Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)

  A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported

  Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

Secondary Outcomes (4)

• To determine the single oral dose pharmacokinetic profiles of RAY1225(AUC0-∞)

  Baseline through Day 29 (Part A)

• To determine the multiple oral dose pharmacokinetic profiles of RAY1225(AUC0-∞)

  Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

• To determine the Pharmacodynamics of RAY1225(Change in Body Weight）

  Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

• To determine the Pharmacodynamics of RAY1225（Change in Waist circumference）

  Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

Study Arms (6)

RAY1225(Part A)

EXPERIMENTAL

Escalating doses of RAY1225 administered subcutaneously (SC) once in healthy participants.

Drug: RAY1225

Placebo (Part A)

EXPERIMENTAL

Placebo administered SC once in healthy participants.

Drug: Placebo

RAY1225 (Part B)

EXPERIMENTAL

Escalating doses RAY1225 administered SC once weekly for four weeks in healthy participants.

Drug: RAY1225

Placebo (Part B)

EXPERIMENTAL

Placebo administered SC once weekly for four weeks in healthy participants.

Drug: Placebo

RAY1225(Part C)

EXPERIMENTAL

Three dose levels of RAY1225 administered SC once weekly for four weeks in participants with Obese.

Drug: RAY1225

Placebo (Part C)

EXPERIMENTAL

Placebo administered SC once weekly for four weeks in participants with Obese.

Drug: Placebo

Interventions

Placebo DRUG

Administered SC

Placebo (Part A)

RAY1225 DRUG

Administered SC

RAY1225(Part A)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Signature of a dated Informed Consent Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
• Participants must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
• Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.
• Body weight is no less than 50 kg in males and no less than 45 kg in females. Body mass index (BMI) 18≤BMI\<28 kg/m2（Part A\&B only);BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
• BMI≥28 kg/m2（Part C only）.BMI is determined by the following equation: BMI = weight/height2 (kg/m2).

You may not qualify if:

• Participants with clinically significant disorders (including but not limited to, cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, neurological, psychiatric, cutaneous, hematological disorders, retinopathy, and neoplasms etc. )within 24 weeks prior to randomization.
• Participants who are not suitable for subcutaneous injections (trauma, surgery, allergies or skin lesions, etc.).
• Known history of definite mental illness, such as depression, suicidal ideation, schizophrenia, bipolar disorder.
• Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.
• Participants who experienced a grade 3 hypoglycemic event within the 12 months prior to randomization, or experienced a hypoglycemic event (venous or terminal blood glucose \<3 mmol/L ) ≥3 times or with hypoglycemia-related symptoms within 3 months prior to randomization.
• Participants with clinically significant abnormalities on ECG, or QTcF \>450ms, or with a family history of long QT syndrome or a family history of Brugada syndrome.
• Participants who planning to use glucagon-like peptide-1 (GLP-1) receptor agonists and GLP1-related drugs or other enteroglucagon peptides(including but not limited to: exenatide, liraglutide, lisnatide, benalutide, dulaglutide, lorcetide, semaglutide, tirzepatide), during the 12 weeks prior to randomization or during the trial.
• Participants who undergone major surgery, donated blood/bleeding profusely (\> 400 mL) 12 weeks prior to randomization, donated blood/bleeding profusely (\>200 mL) 4 weeks prior to randomization,or have a serious infection.
• The average daily smoking are more than 5 cigarettes within 12 weeks prior to screening or unwilling to quit smoking during the study period.
• Participants who may not complete the study for other reasons or should not be included in the study in the opinion of the investigator.
• Known presence of a single genetic mutation, other diseases or medications causing obesity, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, growth hormone deficiency, acromegaly, pseudohypoparathyroidism, hypogonadism, or weight gain caused by increased non-fat content (e.g., edema)\[Part C only\]

Sponsors & Collaborators

• Guangdong Raynovent Biotech Co., Ltd: lead

Study Sites (1)

Nanfang Hospital,South Medical Hospital

Guangzhou, Guangdong, China

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 11, 2023
• First Posted: April 28, 2023
• Study Start: May 18, 2023
• Primary Completion: March 1, 2024
• Study Completion: March 23, 2024
• Last Updated: March 5, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)